News Archivi - Amiko
181
archive,category,category-news,category-181,ajax_fade,page_not_loaded,,qode-theme-ver-13.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.5,vc_responsive

News

  Sanner and Amiko partner to develop digital solutions for true medication adherence Bensheim/Germany, London/UK, 13 February 2018 – How can artificial intelligence, drug delivery systems and add-ons help to improve true medication adherence? By combining long-standing experience in custom-made pharmaceutical packaging, dosing and delivery systems with advanced...

Amiko receives CE mark for use of the Respiro Platform with Teva’s Spiromax® Inhaler, Chiesi's Nexthaler® inhaler and GlaxoSmithKline's Ellipta® inhaler London, UK. Feb. 5, 2018 — Amiko Digital Health Limited (Amiko), a company that develops advanced medication sensor technologies and AI-powered digital health tools, announced today that...

Amiko Digital Health announces the investment from strategic investors Sanner and Breed Reply London, UK. Dec. 18, 2017 — Amiko Digital Health Limited (Amiko), a company that develops advanced medication sensor technologies and AI-powered digital health tools, today announced the closing of a new financing round,...

  Amiko’s Respiro awarded with the 1st prize at the IBM Watson AI XPRIZE’s annual Milestone Awards Los Angeles, US. Dec. 8, 2017 — Amiko Digital Health Limited (Amiko), provider of advanced medication sensor technologies and AI-powered digital health tools, announced that the company has been recognized...